Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Receptor Protein-Tyrosine Kinases
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).